In conclusion, our study shows for the first time that paricalcitol, compared to calcitriol, exerts a beneficial effect on Hb levels in patients with advanced CKD independent of several confounding factors involved in anemia pathogenesis, like inflammation and PTH levels. Here, GSTM1 is linked to chronic kidney disease.